/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Mersana Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$27.9709 0.012(1.2%) MRSN at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 27.55
Highest Today 27.84
Today’s Open 27.55
Prev. Close 27.52
52 Week High 70.73
52 Week Low 5.21
Day’s Range: Low 27.55 High 27.84
52-Week Range: Low 5.21 High 70.73
1 day return -
1 Week return +1.19
1 month return +240.75
3 month return +289.37
6 month return +7554.66
1 year return +1129.13
3 year return +294.33
5 year return +19.89
10 year return -

Institutional Holdings

Nextech Invest, Ltd. 9.67

Bain Capital Life Sciences Investors, LLC 6.94

Vanguard Group Inc 6.71

BlackRock Inc 6.67

Schonfeld Strategic Advisors LLC 6.10

AQR Capital Management LLC 4.12

Rock Springs Capital Management LP 3.06

Vanguard Total Stock Mkt Idx Inv 2.72

SILVERARC CAPITAL MANAGEMENT, LLC 2.48

State Street Corp 2.09

Geode Capital Management, LLC 1.96

Vanguard Explorer Inv 1.61

Catalio Capital Management, LP 1.37

683 Capital Management LLC 1.32

Jacobs Levy Equity Management, Inc. 1.07

5AM Venture Management, LLC 1.05

Qube Research & Technologies 0.94

Vanguard Institutional Extnd Mkt Idx Tr 0.84

Northern Trust Corp 0.69

Renaissance Technologies Corp 0.67

Deutsche Bank AG 0.67

IEQ CAPITAL, LLC 0.57

Lion Point Capital, LP 0.52

iShares Biotechnology ETF 0.48

Vanguard VIF Small Co Gr 0.33

Extended Equity Market Fund K 0.17

Vanguard Market Neutral I 0.09

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

NT Ext Equity Mkt Idx Fd - NL 0.07

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

NT Col R2000 Val Idx Fd -DC -L -TierFour 0.05

Vanguard Instl Ttl Stck Mkt Idx Tr 0.04

Russell 2500™ Index Fund F 0.04

U.S. Equity Market Fund F 0.03

Russell 2000 Index Non-Lendable Fund E 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Extended Equity Market Fund M 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

China Universal NASDAQ Bio-Tch ETF(QDII) 0.02

Market Status

Strong Buy: 8

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 137.57 M

PB Ratio 32.0262

PE Ratio 0.0

Enterprise Value 83.02 M

Total Assets 144.66 M

Volume 30741

Company Financials

Annual Revenue FY23:40842000 40.8M, FY22:26581000 26.6M, FY21:43000 0.0M, FY20:828000 0.8M, FY19:42123000 42.1M

Annual Profit FY23:null 0.0M, FY22:26581000 26.6M, FY21:43000 0.0M, FY20:828000 0.8M, FY19:42123000 42.1M

Annual Net worth FY23:-197050000 -197.1M, FY22:-207540000 -207.5M, FY21:-169205000 -169.2M, FY20:-88404000 -88.4M, FY19:-27197000 -27.2M

Quarterly Revenue Q3/2025:11009000 11.0M, Q2/2025:3056000 3.1M, Q1/2025:2754000 2.8M, Q3/2024:12598000 12.6M, Q2/2024:2293000 2.3M

Quarterly Profit Q3/2025:11009000 11.0M, Q2/2025:2769000 2.8M, Q1/2025:2754000 2.8M, Q3/2024:12598000 12.6M, Q2/2024:-14952000 -15.0M

Quarterly Net worth Q3/2025:-7545000 -7.5M, Q2/2025:-24296000 -24.3M, Q1/2025:-24123000 -24.1M, Q3/2024:-11501000 -11.5M, Q2/2024:-24268000 -24.3M

Fund house & investment objective

Company Information Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 102

Industry Biotechnology

CEO Dr. Martin H. Huber M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow